Source: dvm360
A study by Akston Biosciences introduces AKS-107, an antigen-specific immunotherapy, exhibiting potential to eliminate insulin-specific ß cells, published in Frontiers in Immunology. AKS-107 prevented spontaneous diabetes in nonobese mice and insulin-reactive ß cell receptor transgenic mouse strains, positioning it as a promising Type 1 diabetes (T1D) prevention candidate. Engineered with insulin epitopes binding to ß cell receptors, AKS-107 showed safety and sustained pharmacokinetics in mice and primates. Akston, collaborating with Dechra Pharmaceuticals PLC, extends its therapeutic focus to companion animal insulin therapies like AKS-321d and AK425c for canine and feline diabetes.
These novel therapies enable once-weekly injections, based on Akston’s Ambifect Fc-fusion protein platform. This platform streamlines therapeutic development, recognized for its versatility in diverse treatment areas, including autoimmune diseases and extended-duration insulin therapies. Akston’s commitment to revolutionize Veterinary health, evidenced by its investment in manufacturing and adoption of innovative technologies, underscores its dedication to addressing various needs in the Animal Health space.
Read the full story HERE: https://www.dvm360.com/view/therapeutic-development-platform-demonstrates-versatility